Malaysia Cardiovascular Diseases Therapeutics Market Report 2022 to 2030

Malaysia Cardiovascular Diseases Therapeutics Market Analysis

$ 3999

The Malaysia cardiovascular disease therapeutics market is projected to grow from $261 Mn in 2022 to $464 Mn in 2030 with a CAGR of 7.42% for the year 2022-2030. The rising elderly population and increased prevalence of cardiovascular diseases in Malaysia are the major factors responsible for the growth of the market. The Malaysia cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Xepa-Soul Pattinson, Hyphens Pharma, and Novartis are the major players in the Malaysia cardiovascular disease therapeutics market.

ID: IN10MYPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Dr. Parul Choudhary

Buy Now

Malaysia Cardiovascular Disease Therapeutics Market Executive Analysis

The Malaysia cardiovascular disease therapeutics market size is at around $261 Mn in 2022 and is projected to reach $464 Mn in 2030, exhibiting a CAGR of 7.42% during the forecast period. The Health Ministry will receive one of the biggest allocation increases in Budget 2023, amounting to $8.05 Bn compared to $7.23 Bn this year, as the government continues to improve the capacity of public health services. A total of $1.09 Bn has been allocated for the purchase of items like medications, reagents, vaccines, and disposable equipment, a rise of 12% from 2022.

Malaysia is experiencing a rise in the prevalence of Non-Communicable Diseases (NCD) as a consequence of demographic and socioeconomic changes brought on by economic development. In Malaysian hospitals, Cardiovascular Disease (CVD) related mortality increased sharply from 15.7% in 1996 to 25.4% in 2006, and it is predicted that this trend will continue in the coming decades.

Two metabolic routes are involved in the metabolism of the second-generation thienopyridine antiplatelet drug, clopidogrel, which is also a prodrug. Clinically, about one-fourth of people taking clopidogrel show a sub-therapeutic response; the loss-of-function genotype reduces clopidogrel's ability to inhibit platelets by decreasing clopi-H4 levels. With the development of personalized medicine, doctors are now better able to address the effects of genetic variability on clopidogrel therapy. Regarding the clinical utility of these genetic methods, there are some divergent opinions.

Malaysia Cardiovascular Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The Malaysia cardiovascular disease therapeutics market is being driven by the increase in cardiovascular illnesses like hypertension, heart failure, and coronary artery disease. Cardiovascular diseases are more likely to form in people who live unhealthy lifestyles and eat unhealthy foods, such as those involving smoking, inactivity, and a high-fat diet. As a result, there is now more demand for therapeutics that can be used to treat or stop these illnesses. The National Strategic Plan for Non-Communicable Diseases is just one of the programs the Malaysian government has put into place to encourage the control and prevention of cardiovascular diseases.

Market Restraints

Treatment for cardiovascular disease can be costly, particularly for those who need ongoing care. For some people, this might restrict their access to care. Many Malaysians remain ignorant of the risk factors and the significance of managing cardiovascular diseases despite government efforts. Delays in diagnosis and treatment may lead to subpar health results in the end. Cardiovascular disease medicines may cause side effects in some patients, which may restrict their use or cause them to stop taking them altogether thereby limiting the growth of Malaysia's cardiovascular disease therapeutics market.

Competitive Landscape

Key Players

Pharmaniaga (MYS)
Sunward Pharmaceutical (MYS)
Antah (MYS)
Xepa-Soul Pattinson (MYS)
Hyphens Pharma (MYS)
Novartis
Mylan
Teva Pharmaceutical
Zydus
Pfizer
Lupin
GSK

Healthcare Policies and Regulatory Landscape

To shield Malaysians from the high expenses of healthcare, the National Health Financing Scheme was established. It seeks to guarantee that everyone has access to reasonably priced healthcare services, including treatment for cardiovascular disease. The National Cardiovascular Disease Database was created to gather information on cardiovascular disease afflicted and their therapies, allowing medical professionals to track disease trends and enhance therapeutic results. The Malaysian government controls drug costs to make sure that they are still reasonable and available to patients. The government has also launched programs to encourage the use of generic drugs as an accessible substitute for named ones.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

Hypertension
Coronary Artery Disease
Hyperlipidaemia
Arrhythmia
Others

By Drug Type (Revenue, USD Billion):

Antihypertensive
Anticoagulants
Antihyperlipidemic
Antiplatelet Drugs
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.